Health Care · Pharmaceutical Preparations · Nasdaq · CIK 2012593 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $40.94Day −2.43%Mkt cap $2.0B1Y +165.5%Off 52W high −7.5%Vol (1Y) 136.3%
Daily closing price, split-adjusted to the current basis; 2.1y shown of 533 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest5.6% of sh out |
| Days to cover6.1d |
| 13F net flow (QoQ)+0.87% |
| Top-10 13F concentration66.4% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$107.3M |
| ROE−28.2% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+34.9% |
| 1Y+165.5% |
| Since incept. (ann.)+37.2% |
Total return through 2026-07-29 · series begins 2024-06-07. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)136.3% |
| Ann. volatility (3Y)122.2% |
| Sharpe (1Y)1.12 |
| Sharpe (3Y)0.75 |
| Max drawdown (1Y)−28.8% |
| Max drawdown (3Y)−75.5% |
| Beta (3Y vs SPY)0.96 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 7.2M | $224M | — | +0.8% |
| TRV GP V, LLC | 7.1M | $223M | — | +0.0% |
| ARCH Venture Management, LLC | 3.7M | $117M | — | +0.0% |
| Capital International Investors | 3.1M | $97M | — | −9.0% |
| Cormorant Asset Management, LP | 3.0M | $93M | — | −2.3% |
| GOLDMAN SACHS GROUP INC | 2.9M | $92M | — | −2.0% |
| BlackRock, Inc. | 2.5M | $78M | — | +3.0% |
| Sofinnova Investments, Inc. | 1.9M | $60M | — | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding suppressed: the summed institutional 13F holdings (52,482,931) exceed the cover-page shares-outstanding count for this quarter (47,792,943, as of 2026-03-02) by more than securities-lending double counting can explain (FINRA short interest 3,048,448 shares at 2026-04-30), so the share count is stale or wrong (common for annual 20-F foreign private issuers after a share issuance) and a percentage would be fabricated. Holder share counts are shown as filed.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.42 | — | $20.0M | — |
| 2025-09-30 | 2025-11-06 | −$0.71 | — | — | — |
| 2025-06-30 | 2025-08-07 | −$0.75 | — | — | — |
| 2025-03-31 | 2025-05-08 | −$0.68 | — | $0 | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
